pff teal = 0+160+175 main colors pff green = 120+162+47 light green = 193+216+47 red = 242+102+73...
DESCRIPTION
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, Toby Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5): , September 2015.TRANSCRIPT
PRECISION MEDICINE FOR IPF: DREAM OR REALITY?
IMRE NOTH, MDCLINICAL CARE: NEW AND EVOLVING TREATMENT STRATEGIES NOVEMBER 14, 2015
What is “Precision” Medicine?• Precision medicine is an emerging approach for disease treatment and
prevention that takes into account individual variability in genes, environment, and lifestyle for each person.
– Environment/Lifestyle– Genes– Treatments
• “IPF, like other complex, multipathway diseases, has the potential to benefit from developments in personalized care in several ways, including identification of individuals at risk, development of more accurate and less invasive diagnostic tools, improved understanding of the multitude of profibrotic pathways involved in disease biology, identification of therapeutic targets and improved early phase clinical trial design, prediction of outcome and prioritization of lung transplant and prediction of response to treatment (e.g. efficacy and toxicity markers). The availability of effective therapeutic options for patients with IPF makes the need for markers of diagnosis, prognosis and disease behavior greater than ever”
1. NIH Precision Medicine Initiative2. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises.Curr Opin Pulm Med. 2015. Sep;21(5):470-8.
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, TobyPersonalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5):470-478, September 2015.
What “Promises/Dreams” for the Future?
“Precision” Treatment of Comorbidities in IPF
• GERD• CAD• Thyroid• OSA• Pulmonary hypertension• Pulmonary embolism• Emphysema• Obesity• Depression and anxiety
B. Axial image
A. Coronal with thickened gastric mucosa above the level of the diaphragm
Noth I, et al Eur Respir J. 2012 Feb;39(2):344-51. Epub 2011 Jul 7.
GERD: Improved Survival with Treatment
Lee. AJRCCM. 2011;184:1390-1394.
WRAP trial
• Can Nissen fundoplication alter disease progression in IPF in patients with positive pH probes?
• Randomized trial.
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, TobyPersonalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5):470-478, September 2015.
IPF Patients Had Higher Bacterial Load than COPD or Healthy Controls
Molyneaux et al; AJRCCM 2014; 190: 906-13
Differences in OTU Frequencies Between IPF and Control Subjects
Molyneaux et al; AJRCCM 2014; 190: 906-13
IPF Patients in the Tertile With the Highest Bacterial Load Have Worst Prognosis
Molyneaux et al; AJRCCM 2014; 190: 906-13
Adjusted Event Free Survival CurvesStratified by Presence of
Staphylococcus & Streptococcus
Han et al; Lancet Respir Med 2014; 2: 548-56
Co-trimoxazole Decreases All Cause Mortality in Per Protocol Analysis in 181 Fibrotic IIP (89% IPF)
Shulgina et al; Thorax 2013; 68: 155-62
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, TobyPersonalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5):470-478, September 2015.
Figure 2. Hierarchical clustering discriminates subgroups with outcome differences in the replication cohort (A) Hierarchical clustering of IPF patients from the replication cohort (n=75) based on the 52-gene signature found in the discovery cohort to be associated with TFS (FDR<5%, Cox score above 2.5 or below -2.5). Two major clusters of IPF patients were identified. Every row represents a gene and every column a patient. Color scale is shown adjacent to heatmap in log based two scale – generally, yellow denotes increase over the geometric mean of samples and purple decrease. (B) Transplant-free survival differs between clusters in the replication cohort. P-value determined by the Log-rank test.
Herazo-Maya et al Science Trans Med 2013
Herazo-Maya et al Science Trans Med 2013
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, TobyPersonalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5):470-478, September 2015.
The Future – can we integrate these data?
WGCNA Modules with EMT and T-cell Regulation, Map to Altered Lung Microbial Community
Spagnolo, Paolo; Tzouvelekis, Argyris; Maher, TobyPersonalized medicine in idiopathic pulmonary fibrosis: facts and promises. Current Opinion in Pulmonary Medicine. 21(5):470-478, September 2015.
TLR3 and IPF
Figure 5. The Toll-like receptor 3 L412F polymorphism is associated with accelerated disease progression in idiopathic pulmonary fibrosis (IPF). FVC is an established measure of disease progression in IPF. The longitudinal rate of decline in FVC (% of predicted value) in variant-CT/TT genotype patients with IPF compared with CC genotype wild-type patients is significantly greater at 48 weeks and 96 weeks follow-up, respectively. Absolute difference of −7.1% (P = 0.012) and −8.9% (P = 0.024) change from baseline % predicted.
O’Dwyer et al. Am J Respir Crit Care Med 188, 1442-1450.
MUC5B, a Genetic Determinant of Survival in Idiopathic Pulmonary Fibrosis
0 200 400 600 800 1000 1200
0.2
0.4
0.6
0.8
1.0
Days of Follow-up
Sur
viva
l
| || ||| |||| | |||| ||||||||||||| ||||||| |||||||||||| ||| | | | ||| |||||| ||||| | |
||| || | || |||||||||||||||| | | ||||| | || || | ||| | |
||
|||| || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| ||||||||||||| |||||||||||||| |||||| ||| ||||||||||||| | |||| || ||| ||||||||||||||| ||| | ||||||||||||||||||||| ||
| || || | | | |
| |||| || | | | || ||| | | | | | | | | |
| | | | |
TTGTGG
InterMune
0 500 1000 1500 2000
0.2
0.4
0.6
0.8
1.0
Days of Follow-up
Sur
viva
l | |
||
||
|
| | | | | || |
||| ||
||
| || | | |||||| |
| |||||||
|| | | |||
|| |||||
||| | |
| | | | | || |||||| | | |
| | | |
| | |
TTGTGG
Chicago
Pelito et al JAMA 2013
• Multivariable analysis of known variables associated survival – FVC%, DLCO%, Age,
Gender, tobacco
• TOLLIP (HR 1.72) and MUC5B (HR 1.70) maintained significance
Additive Predictive Value of TOLLIP and MUC5B
KM plot for TOLLIP*/MUC5B risk alleles. Black =0,0 Blue = 0,1 (presence of risk alleles in both TOLLIP and MUC5B) Green = 1,0 Brown = 1,1 Red = 2,0 (absence of risk alleles in both TOLLIP and MUC5B). *homozygote minor cases in TOLLIP not included.
“Precision” therapy by genotype?
PANTHER StudyIPF patients ages 35–85 years with FVC ≥ 50%, DLco ≥ 3% were randomized to
either N-acetylcysteine (NAC) alone; prednisone, azathioprine,and NAC combination; or placebo. Combination therapy stopped early.
*At time of clinical alert, NAC alone (n = 81) and placebo (n = 78).PANTHER = Prednisone, Azathioprine and N-acetylcysteine: A Study That Evaluates Response in IPF; FVC = forced vital capacity.Raghu G, et al. N Engl J Med. 2012;366(21):1968–1977. Martinez FJ, et al. N Engl J Med. 2014;370(22):2093–2101.
IPFpatientsn = 341
R
NAC alone*n = 131
Placebo*n = 131
Prednisone, azathioprine,and NAC (n = 77)
60-week follow-up
1o endpoint: FVC
2o endpoint:Death; acuteexacerbation;
diseaseprogression
STOP
PANTHER Part A: Results
Raghu G, et al. N Engl J Med. 2012;366(21):1968–1977.
Combination therapy of prednisone, azathioprine, and NACwas stopped early for evidence of harm
00
Prob
abili
ty o
f dea
thor
hos
pita
lizat
ion
1.0
0.8
Weeks since randomization30
0.4
60
0.6
0.2
Combination therapyPlacebo
15 45
0.1
0.9
0.5
0.7
0.3
PANTHER Part B: ResultsNAC alone showed no difference in FVC decline or
any secondary endpoints compared to placebo
Martinez FJ, et al. N Engl J Med. 2014;370(22):2093–2101.
Baseline−0.20
FVC
(lite
rs)
0
−0.10
Week30 60
AcetylcysteinePlacebo
15 45
−0.05
−0.15
NAC Effectiveness by TOLLIP Genotype
Composite endpoint of FVC decline, hospitalization, death or transplant
Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, Huang Y, Strek ME, Noth I. Am J Respir Crit Care Med. 2015 Sep 2.
Conclusions
• “Precision” in IPF is already a reality and growing• Genetics can predict outcomes• Validated biomarkers have been growing• Treatment strategies focused on comorbidities is a
“precision” approach• Pharmacogenomics – is it possible that we’ll treat IPF
the same way we do breast cancer?